Revenue (Tables)

6 Months Ended

Jun. 30, 2020

Revenue

Schedule of revenue recognized from collaborative arrangements

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2020		2019		2020		2019
Janssen	$	5,479	$	7,392	$	12,101	$	12,715
Other		9		101		19		116
Total collaboration revenue	$	5,488	$	7,493	$	12,120	$	12,831

Summary of changes in deferred revenue

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2020		2019		2020		2019
Collaboration revenue recognized in the period from:
Amounts included in deferred revenue at the beginning of the period	$	5,488	$	7,493	$	12,120	$	12,825
Performance obligations satisfied in previous period		—		—		—		—

Summary of profit sharing revenue and collaboration loss

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2020		2019		2020		2019
Mylan collaboration agreement - Amounts receivable from Mylan	$	9,520	$	157	$	21,250	$	157
Collaboration loss - Amounts payable to Mylan	$	—	$	181	$	—	$	1,582

Summary of the reductions to R&D costs related to reimbursement payments

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2020		2019		2020		2019
Janssen	$	1,563	$	784	$	2,770	$	2,195
Mylan		351		31		1,622		234
Total reduction to R&D expense	$	1,914	$	815	$	4,392	$	2,429